[ReneSola Appoints President of China Division JIASHAN, China, March 26, 2012 ReneSola CEO Mr. Xianshou Li remarked, “While China leads the world in the number of solar panels exported, it lags behind many countries in terms of the number of solar panels installed. This is changing, however, and we believe the Chinese market has impressive growth prospects. In 2012, we] []
[ReneSola Appoints President of China Division JIASHAN, China, March 26, 2012 ReneSola CEO Mr. Xianshou Li remarked, “While China leads the world in the number of solar panels exported, it lags behind many countries in terms of the number of solar panels installed. This is changing, however, and we believe the Chinese market has impressive growth prospects. In 2012, we] []
[Registration No. 333-163563 Post Effective Amendment No.1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Tianyin Pharmaceutical Co., Inc. Delaware (State or other jurisdiction of incorporation or organization) 20-4857782 (I.R.S. Employer Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 Renmin Road South, Chengdu, P. R. China, 610041 +0086-28-86154737 Dr. Guoqing Jiang Chief Executive Officer] [HUNTER TAUBMAN WEISS LLP 17 State Street, Suite 2000 New York, New York 10007 (212) 732-7184 Fax: (212) 202-6380 E-mail: LTaubman@htwlaw.com March 27, 2012 Tianyin Pharmaceutical Co., Inc. 23rd Floor, Unionsun Yangkuo Plaza No. 2, Block 3, Renmin Road South Chengdu, P. R. China, 610041 Ladies and Gentlemen: In so acting, we have examined and relied upon the originals or] [Patrizio & Zhao, LLC Certified Public Accountants and Consultants 322 Route 46 West Parsippany, NJ 07054 Fax: (973) 882-0788 www.pzcpa.com Member of Alliance of worldwide accounting firms CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the use in the Post-Effective Amendment No. 1 to a Registration Statement on Form S-1 pertaining to the registration of 15,784,640 shares of]
[Registration No. 333-163563 Post Effective Amendment No.1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Tianyin Pharmaceutical Co., Inc. Delaware (State or other jurisdiction of incorporation or organization) 20-4857782 (I.R.S. Employer Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 Renmin Road South, Chengdu, P. R. China, 610041 +0086-28-86154737 Dr. Guoqing Jiang Chief Executive Officer] [HUNTER TAUBMAN WEISS LLP 17 State Street, Suite 2000 New York, New York 10007 (212) 732-7184 Fax: (212) 202-6380 E-mail: LTaubman@htwlaw.com March 27, 2012 Tianyin Pharmaceutical Co., Inc. 23rd Floor, Unionsun Yangkuo Plaza No. 2, Block 3, Renmin Road South Chengdu, P. R. China, 610041 Ladies and Gentlemen: In so acting, we have examined and relied upon the originals or] [Patrizio & Zhao, LLC Certified Public Accountants and Consultants 322 Route 46 West Parsippany, NJ 07054 Fax: (973) 882-0788 www.pzcpa.com Member of Alliance of worldwide accounting firms CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the use in the Post-Effective Amendment No. 1 to a Registration Statement on Form S-1 pertaining to the registration of 15,784,640 shares of]
[CHINA LIFE INSURANCE COMPANY LIMITED (A joint stock limited company incorporated in the Peoples Republic of China with limited liability) (the Company) (Stock Code: 2628) IMPORTANT Announcement on the Resolutions of the Seventeenth Meeting of the Third Session of the Board of Directors of China Life Insurance Company Limited The seventeenth meeting (the Meeting) of the third session of the] [CHINA LIFE INSURANCE COMPANY LIMITED (A joint stock limited company incorporated in the Peoples Republic of China with limited liability) (the Company) (Stock Code: 2628) IMPORTANT Announcement on Resolutions of the Sixteenth Meeting of the Third Session of the Board of Supervisors China Life Insurance Company Limited (the Company) The sixteenth meeting (the Meeting) of the third session of the] [Description 99.1 99.2]
[FORM 10-K (Mark One) x December 31, 2011 For the fiscal year ended: Or For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, Maryland 20-8747899 (State or other jurisdiction oforporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province Peoples Republic of China] [List of subsidiary / variable interest entities of Biostar Pharmaceuticals, of December 31, 2011 Subsidiary Place oforporation Shaanxi Biostar BioTech Peoples Republic of China Variable interest entities Place oforporation Shaanxi Aoxing Pharmaceutical Peoples Republic of China Shaanxi Weinan Aoxing Pharmaceuticals, Peoples Republic of China] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, We herebynsent to yourorporation of our audit reportted March 27, 2012 relating to thensolidated financial statements of Biostar Pharmaceuticals, of and for each of the years ended December 31, 2011 and 2010 in the Annual Report on Form 10-K of] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, (No. 333-161598) We herebynsent to theorporation by reference in the Registration Statement on Form S-8 Mazars CPA Limited Certified Public Accountants Hong Kong March 27, 2012 ex23-2.htm 4 EX-23.2] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this annual 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with] [CERTIFICATION I, Zack Zibing Pan, certify that: 1. I have reviewed this annual 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Ronghua Wang Chief Executive Officer ex32-1.htm 7 EX-32.1] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Zack Pan Chief Financial Officer (Principal Financial and Accounting Officer) ex32-2.htm 8 EX-32.2]
[CHINA LIFE INSURANCE COMPANY LIMITED (A joint stock limited company incorporated in the Peoples Republic of China with limited liability) (the Company) (Stock Code: 2628) IMPORTANT Announcement on the Resolutions of the Seventeenth Meeting of the Third Session of the Board of Directors of China Life Insurance Company Limited The seventeenth meeting (the Meeting) of the third session of the] [CHINA LIFE INSURANCE COMPANY LIMITED (A joint stock limited company incorporated in the Peoples Republic of China with limited liability) (the Company) (Stock Code: 2628) IMPORTANT Announcement on Resolutions of the Sixteenth Meeting of the Third Session of the Board of Supervisors China Life Insurance Company Limited (the Company) The sixteenth meeting (the Meeting) of the third session of the] [Description 99.1 99.2]
[(A joint stock limited company incorporated in the Peoples Republic of China with limited liability) (Stock Code: 2628) ANNOUNCEMENT OF RESULTS FOR THE YEAR ENDED 31 DECEMBER 2011 CHAIRMANS STATEMENT During the Reporting Period, the Companys total revenues reached RMB370,899 million, a decrease of 3.9% from 2010. As at the end of the Reporting Period, the Companys total assets reached] [Description 99.1 Announcement, dated March 26, 2012]
[(A joint stock limited company incorporated in the Peoples Republic of China with limited liability) (Stock Code: 2628) ANNOUNCEMENT OF RESULTS FOR THE YEAR ENDED 31 DECEMBER 2011 CHAIRMANS STATEMENT During the Reporting Period, the Companys total revenues reached RMB370,899 million, a decrease of 3.9% from 2010. As at the end of the Reporting Period, the Companys total assets reached] [Description 99.1 Announcement, dated March 26, 2012]
[KINGOLD JEWELRY REPORTS 2011 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS Company to Hold Conference Call with Accompanying Slide Presentation On March 27, 2011, at 8:30 a.m. ET WUHAN CITY, China, March 26, 2012 -- Kingold Jewelry, Inc. (NASDAQ: KGJI) Mr. Zhihong Jia, Chairman and CEO of Kingold, stated, “We were pleased to report solid operating results in 2011. Our focus] []
